financetom
Business
financetom
/
Business
/
Electrical products maker Hubbell beats Q3 adjusted EPS estimates on data center demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Electrical products maker Hubbell beats Q3 adjusted EPS estimates on data center demand
Oct 28, 2025 5:04 AM

Overview

* Hubbell Q3 revenue grows 4% yr/yr but misses analyst expectations

* Adjusted EPS for Q3 beats analyst estimates, reflecting strong operational performance

* Company raises 2025 adjusted EPS outlook, citing strong margin expansion and lower tax rate

Outlook

* Hubbell raises 2025 adjusted EPS outlook to $18.10-$18.30

* Company anticipates 3-4% organic sales growth for 2025

* Hubbell expects 2025 free cash flow conversion of approximately 90%

Result Drivers

* ELECTRICAL SOLUTIONS GROWTH - 8% organic growth driven by demand in datacenter and light industrial markets

* GRID INFRASTRUCTURE GROWTH - 8% organic growth in Grid Infrastructure due to strong T&D markets and infrastructure investment

* LOWER TAX RATE - Decreased tax rate contributed to earnings growth, driven by international restructuring benefits

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $1.50 $1.54

Revenue bln bln (10

Analysts

)

Q3 Beat $5.17 $4.98

Adjusted (11

EPS Analysts

)

Q3 EPS $4.77

Q3 Net $256.70

Income mln

Q3 23.90%

Adjusted

Operatin

g Margin

Q3 Free $254 mln

Cash

Flow

Q3 22%

Operatin

g Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electrical components & equipment peer group is "buy"

* Wall Street's median 12-month price target for Hubbell Inc ( HUBB ) is $458.00, about 5.2% above its October 27 closing price of $433.98

* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib
RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib
Oct 2, 2024
08:34 AM EDT, 09/30/2024 (MT Newswires) -- RedHill Biopharma ( RDHL ) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of COVID-19. The patent from the US Patent and Trademark Office would be granted on Oct. 15 and be valid through 2041,...
Murdoch's REA ends month-long takeover pursuit of Britain's Rightmove
Murdoch's REA ends month-long takeover pursuit of Britain's Rightmove
Oct 2, 2024
By Aby Jose Koilparambil (Reuters) -Rightmove's shares dropped 8% on Monday after Rupert Murdoch's REA Group ended its $8.29 billion takeover pursuit following a fourth bid rejection from the British real estate portal. Australian property listing firm REA's decision to walk away from making a formal offer for Rightmove ahead of a 1600 GMT deadline capped a month-long saga that...
Mobix Labs Proposes All-Cash Offer for Emcore
Mobix Labs Proposes All-Cash Offer for Emcore
Oct 2, 2024
08:36 AM EDT, 09/30/2024 (MT Newswires) -- Mobix Labs ( MOBX ) said Monday it has submitted a non-binding cash offer to acquire Emcore ( EMKR ) shares for $3.80 per share. The company said the acquisition represents a more than 200% premium over Emcore's ( EMKR ) Sept. 27 stock closing price. Mobix Labs' ( MOBX ) board of...
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Oct 2, 2024
On Monday, Prime Medicine Inc. ( PRME ) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co ( BMY )  to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine ( PRME ) will design optimized Prime Editor reagents for a select number of targets, including reagents...
Copyright 2023-2026 - www.financetom.com All Rights Reserved